Overview

A Study of Nasal Glucagon in Participants With a Common Cold

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety of nasal glucagon (NG) in participants with a common cold, some of whom will also take a nasal decongestant. The study will investigate how the body processes NG and the effect of NG on the body. The study will last up to 30 days for each participant.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Locemia Solutions ULC
Treatments:
Glucagon
Oxymetazoline
Phenylephrine